Sclerostin monoclonal antibody therapy with AMG 785: A potential treatment for osteoporosis

Expert Opinion on Biological Therapy

Volumn 11, Issue 1, 2011, Pages 117-127

  Lewiecki, E Michael ^a  

^a NEW MEXICO CLINICAL RESEARCH AND OSTEOPOROSIS CENTER   (United States)

Author keywords

anabolic; inhibition; osteoanabolic; osteoporosis; PTH; sclerostin

Indexed keywords

ALENDRONIC ACID; ALKALINE PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; AMG 167; AMG 785; BAZEDOXIFENE; CALCIUM ION; CARBOXY TERMINAL TELOPEPTIDE; CDP 1671; CDP 7851; DENOSUMAB; DRUG ANTIBODY; ESTROGEN; IBANDRONIC ACID; LASOFOXIFENE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; MEDROXYPROGESTERONE; MONOCLONAL ANTIBODY; N TERMINAL PROPEPTIDE OF TYPE 1 PROCOLLAGEN; ODANACATIB; OSTEOCALCIN; PARATHYROID HORMONE[1-34]; PROCOLLAGEN; RALOXIFENE; RECOMBINANT PARATHYROID HORMONE; RISEDRONIC ACID; SALCATONIN; SCLEROSTIN; SCLEROSTIN MONOCLONAL ANTIBODY; STRONTIUM RANELATE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ALKALINE PHOSPHATASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTHRALGIA; AUTOSOMAL RECESSIVE DISORDER; BACKACHE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EXPOSURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMUR NECK; FRACTURE; FRACTURE HEALING; FRAGILITY FRACTURE; HEADACHE; HEPATITIS; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE ERYTHEMA; INTRAMEDULLARY NAILING; LIVER FUNCTION TEST; MORPHOMETRICS; OSSIFICATION; OSTEOBLAST; OSTEOCYTE; OSTEOLYSIS; OSTEOPOROSIS; OSTEOSCLEROSIS; POSTMENOPAUSE OSTEOPOROSIS; QUANTITATIVE ANALYSIS; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VAN BUCHEM DISEASE;

ANTIBODIES, MONOCLONAL; BONE MORPHOGENETIC PROTEINS; GENETIC MARKERS; HUMANS; OSTEOPOROSIS;

EID: 78650074746     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2011.540565     Document Type: Review

References (95)

1. Klibanski A, Adams-Campbell L, Bassford T, et al. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285(6):785-95
2. Kanis JA.; On behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical report. World Health Organization Collaborating Centre for metabolic bone diseases, Printed by the University of Sheffield, University of Sheffield, UK;2007
3. National Osteoporosis Foundation: America's Bone Health: The state of osteoporosis and low bone mass in our nation. National Osteoporosis Foundation, Washington, DC; 2002
4. US Department of Health and Human Services: Bone Health and Osteoporosis: A Report of the Surgeon General. US Department of Health and Human Services, Office of the Surgeon General, Rockville, MD
5. Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res 2000;54(Suppl):58-63
6. Riggs BL, Melton LJ III. The worldwide problem of osteoporosis: Insights afforded by epidemiology. Bone 1995;17(Suppl):505S-11S
7. Cooper C, Atkinson EJ, Jacobsen SJ, et al. Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993;137:1001-5
8. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007;22(3):465-75
9. Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporos Int 2005;16(3):229-38
10. Bonewald LF. Chapter 4. Osteocytes. primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, DC; 2008. p. 22-7
11. Cowin SC, Moss-Salentijn L, Moss ML. Candidates for the mechanosensory system in bone. J Biomech Eng 1991;113(2):191-7
12. Lanyon LE. Osteocytes, strain detection, bone modeling and remodeling. Calcif Tissue Int 1993;53(Suppl 1):S102-6
13. Poole KE, Van Bezooijen RL, Loveridge N, et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J 2005;19(13):1842-4
14. Van Bezooijen RL, Roelen BA, Visser A, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 2004;199(6):805-14
15. Riggs BL, Parfitt AM. Drugs used to treat osteoporosis: The critical need for a uniform nomenclature based on their action on bone remodeling. J Bone Miner Res 2005;20(2):177-84
16. Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
17. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291(14):1701-12
18. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995;333:1437-43
19. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41
20. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures - Results from the fracture intervention trial. JAMA 1998;280(24):2077-82
21. Mcclung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
22. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83-91
23. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999;282(14):1344-52
24. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19(8):1241-9
25. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007;356(18):1809-22
26. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007;357(18):1799-809
27. Cummings SR, San Martin J, Mcclung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009;361(8):756-65
28. Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109(4):267-76
29. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene - Results from a 3-year randomized clinical trial. JAMA 1999;282(7):637-45
30. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: Results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008;23(12):1923-34
31. Cummings SR, Eastell R, Ensrud K, et al. The effects of lasofoxifene on fractures and breast cancer: 3-year results from the PEARL trial. J Bone Miner Res 2008;23(Suppl 1):S81
32. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
33. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: A randomized trial. Ann Intern Med 2007;146(5):326-39
34. Reginster JY, Seeman E, DE Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90(5):2816-22
35. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350(5):459-68
36. Ettinger B, Pressman A, Schein J. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Am J Man Care 1998;4:1377-82
37. Curtis JR, Carbone L, Cheng H, et al. Longitudinal trends in use of bone mass measurement among older Americans, 1999-2005. J Bone Miner Res 2008;23(7):1061-7
38. Delmas PD, van De Langerijt L, Watts NB, et al. Underdiagnosis of vertebral fractures is a worldwide problem: The IMPACT study. J Bone Miner Res 2005;20(4):557-63
39. Vestergaard P, Rejnmark L, Mosekilde L. Osteoporosis is markedly underdiagnosed: A nationwide study from Denmark. Osteoporos Int 2005;16(2):134-41
40. Panneman MJ, Lips P, Sen SS, Herings RM. Undertreatment with anti-osteoporotic drugs after hospitalization for fracture. Osteoporos Int 2004;15(2):120-4
41. Solomon DH, Finkelstein JS, Katz JN, et al. Underuse of osteoporosis medications in elderly patients with fractures. Am J Med 2003;115(5):398-400
42. Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002;162(19):2217-22
43. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: Relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006;81(8):1013-22
44. Downey TW, Foltz SH, Boccuzzi SJ, et al. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006;99(6):570-5
45. Cramer JA, Gold DT, Silverman SL, Lewiecki EM. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int 2007;18(8):1023-31
46. Lane NE Kelman A. A review of anabolic therapies for osteoporosis. Arthritis Res Ther 2003;5(5):214-22
47. Lewiecki EM. Emerging drugs for postmenopausal osteoporosis. Expert Opin Emerg Drugs 2009;14(1):129-44
48. Truswell AS. Osteopetrosis with syndactyly; a morphological variant of Albers-Schonberg's disease. J Bone Joint Surg Br 1958;40-B(2):209-18
49. Hausen H. Sklerosteose. Berlin, Springer-Verlag, 1967. p. 351-55
50. Gardner JC, Van Bezooijen RL, Mervis B, et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J Clin Endocrinol Metab 2005;90(12):6392-5
51. Hamersma H, Gardner J, Beighton P. The natural history of sclerosteosis. Clin Genet 2003;63(3):192-7
52. Tacconi P, Ferrigno P, Cocco L, et al. Sclerosteosis: Report of a case in a black African man. Clin Genet 1998;53(6):497-501
53. Bueno M, Olivan G, Jimenez A, et al. Sclerosteosis in a Spanish male: First report in a person of Mediterranean origin. J Med Genet 1994;31(12):976-7
54. Stein SA, Witkop C, Hill S, et al. Sclerosteosis: Neurogenetic and pathophysiologic analysis of an American kinship. Neurology 1983;33(3):267-77
55. Sugiura Y, Yasuhara T. Sclerosteosis. A case report. J Bone Joint Surg Am 1975;57(2):273-7
56. Beighton P, Davidson J, Durr L, Hamersma H. Sclerosteosis -a an autosomal recessive disorder. Clin Genet 1977;11(1):1-7
57. Wergedal JE, Veskovic K, Hellan M, et al. Patients with Van Buchem disease, an osteosclerotic genetic disease, have elevated bone formation markers, higher bone density, and greater derived polar moment of inertia than normal. J Clin Endocrinol Metab 2003;88(12):5778-83
58. Staehling-Hampton K, Proll S, Paeper BW, et al. A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population. Am J Med Genet 2002;110(2):144-52
59. Balemans W, Ebeling M, Patel N, et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 2001;10(5):537-43
60. Brunkow ME, Gardner JC, Van NJ, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 2001;68(3):577-89
61. Veverka V, Henry AJ, Slocombe PM, et al. Characterization of the structural features and interactions of sclerostin: Molecular insight into a key regulator of Wnt-mediated bone formation. J Biol Chem 2009;284(16):10890-900
62. Li X, Zhang Y, Kang H, et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 2005;280(20):19883-7
63. Baron R, Rawadi G. Targeting the Wnt/ beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148(6):2635-43
64. Li X, Ominsky MS, Niu QT, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 2008;23(6):860-9
65. Robling AG, Niziolek PJ, Baldridge LA, et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem 2008;283(9):5866-75
66. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/ beta-catenin signaling. J Bone Miner Res 2009;24(10):1651-61
67. Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: A novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 2005;146(11):4577-83
68. Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007;357(9):905-16
69. Kramer I, Keller H, Leupin O, Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol. Metab 2010;21(4):237-44
70. Niikura T, Hak DJ, Reddi AH. Global gene profiling reveals a downregulation of BMP gene expression in experimental atrophic nonunions compared to standard healing fractures. J Orthop Res 2006;24(7):1463-71
71. Babcook JS, Leslie KB, Olsen OA, et al. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc Natl Acad Sci USA 1996;93(15):7843-8
72. Eddleston A, Marenzana M, Moore AR, et al. A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis. J Bone Miner Res 2009;24(10):1662-71
73. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24(4):578-88
74. Thompson DD, Simmons HA, Pirie CM, Ke HZ. FDA Guidelines and animal models for osteoporosis. Bone 1995;17(4 Suppl):125S-33S
75. Li X, Warmington KS, Niu QT, et al. Effects of co-treatment with anti-sclerostin monoclonal antibody and alendronate in ovariectomized rats. J Bone Miner Res 2008;23(Suppl 1):S60
76. Li X, Warmington K, Niu Q, et al. Increased bone formation and bone mass by sclerostin antibody was not blunted by pretreatment with alendronate in ovariectomized rats with established osteopenia. J Bone Miner Res 2009;24. Available from: Http://www. abstractsonline.com/viewer/ viewAbstractPrintFriendly.asp?CKey= {304C4E90-3D3D-40D8-AC54- 50DC0CC0C371}&SKey={573C1565- EC04-476F-BBF0-182DD52FC667} &MKey={DCB70C83-5B38-431AB0E1- 9221D66718D0}&AKey= {D0C01D4F-E23B-45E2- ACD4- 0AF8AC866B8B
77. Halleux C, Hu B, Diefenbach B, et al. Infrequent co-treatment and sequential treatment of anti-sclerostin antibody with zoledronic acid restores and maintains bone mass in mjurine osteoporosis models. J Bone Miner Res 2009;24. Available from: Http://www. asbmr.org/Meetings/AnnualMeeting/ AbstractDetail.aspx?aid=f1fb064f-3eeb- 4de2-b1bf-0b42453f81b0
78. Kurland ES, Heller SL, Diamond B, et al. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int 2004;15(12):992-7
79. Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J Bone Miner Res 2010;25(5):948-59
80. Agholme F, Li X, Isaksson H, et al. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J Bone Miner Res 2010;25(11):2410-8
81. Li C, Li X, Xiang J, et al. Systemic treatment with a sclerostin monoclonal antibody enhances fracture healing in the rat femoral closed fracture model. J Bone Miner Res 2010;24. Available from: Http://www.asbmr.org/Meetings/ AnnualMeeting/AbstractDetail.aspx? Aid=86bc90c6-c865-462c-8174- e3c1b1029b63
82. Ominsky M, Samadfan R, Jolette J, et al. Sclerostin monoclonal antibody stimulates bone formation and improves the strength and density of the fracture callus and lumbar spine in a primate fibular osteotomy model. J Bone Miner Res 2009;24. Available from: Http:// www.asbmr.org/Meetings/ AnnualMeeting/ AbstractDetail.aspx? aid=169908cb-ad5c-4ef9-a499- be570135fa1d
83. Rey JP, Ellies DL. Wnt modulators in the biotech pipeline. Dev Dyn 2010;239(1):102-14
84. Padhi D, Jang G, Stouch B, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 2010. [Epub ahead of print]
85. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008;84(5):548-58
86. Chen P, Satterwhite JH, Licata AA, et al. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 2005;20(6):962-70
87. Li X, Ominsky MS, Warmington KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J Bone Miner Res 2009;24(4):578-88
88. Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69(3):121-9
89. Bone HG, Mcclung MR, Roux C, et al. Odanacatib, a cathepsin-K inhibitor for osteoporosis: A two-year study in postmenopausal women with low bone density. J Bone Miner Res 2010;25(5):937-47
90. Cosman F, Eriksen E, Recknor C, et al. Effects of once-yearly zoledronic acid 5 mg in combination with teriparatide (PTH) on postmenopausal women with osteoporosis. J Bone Miner Res 2009;24(Suppl 1)
91. Lewiecki EM, Bilezikian JP, Laster AJ, et al. 2009 Santa Fe Bone Symposium. J Clin Densitom 2010;13(1):1-9
92. Bilezikian JP. Chapter 53. Combination anabolic and antiresorptive therapy for osteoporosis. Primer Metabol Bone Dis Disord Miner Metab 2008;7(1):252-4
93. Kansara M, Tsang M, Kodjabachian L, et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J Clin Invest 2009;119(4):837-51
94. Rubin MR, Bilezikian JP. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med 2003;19(2):415-32
95. Mcclung MR, San MJ, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 2005;165(15):1762-8